Literature DB >> 9226734

Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers.

C S Peretti1, J M Danion, F Kauffmann-Muller, D Grangé, A Patat, P Rosenzweig.   

Abstract

The effects of a typical neuroleptic, haloperidol (1 and 2 mg orally), of an atypical neuroleptic, amisulpride (50 and 100 mg) and of a placebo on motor and cognitive skill learning were assessed in 60 healthy volunteers using repeated testing on the Tower of Toronto puzzle. Subjects were asked to solve three blocks of eight trials and, at distance from drug administration, a fourth block. The puzzle was connected to a computer in order to obtain a precise timing of individual moves. Two components of cognitive skill learning were assessed, the ability to learn to solve the puzzle and the acquisition of a problem-solving routine. Subjective feelings of effort and automatisation of the task were assessed using a questionnaire. Like placebo-treated subjects, neuroleptic-treated subjects were able to acquire a motor skill, to learn to solve the puzzle and to acquire a routine. However, haloperidol 2 mg-treated subjects needed significantly more moves to solve the puzzle in blocks 3 and 4, some of them having routinised a non-optimal solution. A significant cognitive slowing was observed in the haloperidol 1 mg group in block 4. The performance pattern and verbal reports suggested that haloperidol impaired the higher cognitive functions such as the ability to shift from one strategy to another and/or to assess one's performance accurately, possibly leading to the development of compensatory strategies. The only deleterious amisulpride effect was a cognitive slowing in block 4, which was observed in the lower dose group.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9226734     DOI: 10.1007/s002130050300

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  12 in total

Review 1.  Biomarkers for the effects of antipsychotic drugs in healthy volunteers.

Authors:  S J de Visser; J van der Post; M S Pieters; A F Cohen; J M van Gerven
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

Review 2.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

Review 3.  Spotlight on amisulpride in schizophrenia.

Authors:  Monique P Curran; Caroline M Perry
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

4.  Modulation of memory and visuospatial processes by biperiden and rivastigmine in elderly healthy subjects.

Authors:  E Wezenberg; R J Verkes; B G C Sabbe; G S F Ruigt; W Hulstijn
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

Review 5.  Amisulpride: a review of its use in the management of schizophrenia.

Authors:  M P Curran; C M Perry
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  Amisulpride: a review of its use in the management of schizophrenia.

Authors:  Kate McKeage; Greg L Plosker
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

7.  Effects of persistent cocaine self-administration on amygdala-dependent and dorsal striatum-dependent learning in rats.

Authors:  Tomoko Udo; Francisco Ugalde; Nina DiPietro; Howard B Eichenbaum; Kathleen M Kantak
Journal:  Psychopharmacology (Berl)       Date:  2004-07       Impact factor: 4.530

8.  Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil.

Authors:  Charles S Peretti; Fabien Gierski; Sophie Harrois
Journal:  Psychopharmacology (Berl)       Date:  2004-05-12       Impact factor: 4.530

9.  Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.

Authors:  Scot E Purdon; Neil Woodward; Stacy R Lindborg; Emmanuel Stip
Journal:  Psychopharmacology (Berl)       Date:  2003-06-24       Impact factor: 4.530

10.  Update on the management of symptoms in schizophrenia: focus on amisulpride.

Authors:  Ann M Mortimer
Journal:  Neuropsychiatr Dis Treat       Date:  2009-05-20       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.